Navigation Links
FDA Advisers Consider New Lupus Drug
Date:11/16/2010

By Steven Reinberg
HealthDay Reporter

TUESDAY, Nov. 16 (HealthDay News) -- U.S. Food and Drug Administration advisers were weighing Tuesday whether to recommend the first new drug in more than 50 years to treat the autoimmune disease lupus.

The drug, belimumab (Benlysta), is a so-called monoclonal antibody drug developed to treat patients who suffer from systemic lupus erythematosus.

In research papers submitted to the advisory committee, the full FDA expressed some concerns about the efficacy and safety of the drug.

"I really do think the drug is efficacious," said Sandra C. Raymond, president & CEO of the Lupus Foundation of America, who was attending the advisory panel meeting. "What I'm hearing in terms of efficacy is pretty strong."

The FDA said it wants the advisory panel to look at both the efficacy data, which according to the agency is modest, and the safety data, which the agency believes raises some serious issues. Specifically, the drug has been linked to depression and suicide.

Raymond noted that many patients with lupus suffer from depression. And many patients in clinical trials testing the drug were also taking antidepressants, she added.

The advisory committee is scheduled to vote on whether the drug's risks are mitigated by the benefits it has to offer to patients who are already receiving standard care.

The agency said it is basing its concerns on the results of two phase 3 trials that compared Benlysta with a placebo.

"The risks associated with belimumab include infection, malignancy, suicidality, and overall number of deaths with a numerical imbalance that favored placebo treatment over belimumab treatment," according to the FDA.

Safety is important, Raymond said, but the drugs used to treat lupus now carry some significant side effects, too. "The safety of some of our medications is not good," she said. "So what are we comparing it to?"

The current treatments include chemotherapy and steroids, which can leave the door open to infections, cancers and other unwanted consequences, Raymond said.

Dr. Joan Merrill, head of Clinical Pharmacology at the Oklahoma Medical Research Foundation and medical director of the Lupus Foundation of America, added that "the safety data on Benlysta looks better than we usually see with biologics."

"We have to keep in mind that there is a natural ceiling on the percentage of patients who can respond to any targeted treatment. We do not yet know exactly how good Benlysta is," Merrill said.

What is known is that Benlysta was shown to be statistically superior to a placebo in two phase 3 trials, she said.

"I hope that the FDA will be able to approve it, after they complete the serious deliberations that they must make on all the data," Merrill said.

Lupus is an autoimmune disease in which the body produces antibodies that attack and destroy healthy tissue. This can damage joints, skin, blood vessels and organs. Benlysta works by inhibiting the production of these antibodies.

Benlysta is made by Human Genome Sciences and GlaxoSmithKline.

While the FDA is not bound by its advisory committees' recommendations it usually does so.

More information

To learn more about lupus, visit the Lupus Foundation of America.

SOURCES: Sandra C. Raymond, President & CEO, Lupus Foundation of America; Joan Merrill, M.D., head, Clinical Pharmacology, Oklahoma Medical Research Foundation, Medical Director, Lupus Foundation of America


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Advisers Back Anemia Drugs for Kidney Patients
2. FDA Advisers Consider Approval of Genetically Modified Salmon
3. FDA Advisers Weigh Approval of Genetically Modified Salmon
4. FDA Advisers Divided on Whether to Ban Diet Drug Meridia
5. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
6. FDA to Broaden Disclosure on Advisers Conflicts of Interest
7. FDA Advisers Urge Stricter Regulation of Tanning Beds
8. Considerable proportion of patients with advanced cancer continue to undergo common cancer screening
9. ConnectedIn Divorce Resource Offers Online Expert Website for People Considering or Going Through Divorce
10. BMEGateway's 20th Anniversary Insurance Symposium considered a “Tremendous” Success
11. Newly Relaunched Autoinsurance.net Offers Consumers Smart Tips To Consider When Purchasing Car Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Advisers Consider New Lupus Drug
(Date:3/22/2017)... ... ... College basketball surges to its peak during the March Madness NCAA tournament, but ... to be foster parents. Through a televised spot, Coach Self is inviting adults to ... abuse, neglect and other family challenges. People who respond to Self’s call to community ...
(Date:3/22/2017)... ... ... HumanHaus is proud to announce the launch of its newest invention on crowdfunding ... invented, but our customers today are busy, energetic, multi-taskers that live in a smarter ... and retired that want to travel. The Sweep&Stand is a self-standing broom ...
(Date:3/22/2017)... ... ... NYC Chiropractor Dr. Steven Shoshany recently helped host a seminar at his cutting edge ... focused on a new protocol for treating pain. Dr. Shoshany is among the first ... the first seminar in the country was hosted at his Integrated Chiropractic Practice. ...
(Date:3/22/2017)... , ... March 22, 2017 , ... Sharon Kleyne is ... more than two decades ago to research evaporation of earth’s and the body’s water ... better health. Also the host of the nationally syndicated radio program, The Sharon Kleyne ...
(Date:3/22/2017)... ... March 22, 2017 , ... The International Association of ... specialists and other medical professionals caring for those suffering from the full spectrum ... iaedp Symposium at the Green Valley Resort in Las Vegas, March 22 - ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 22, 2017 Hologic, Inc. (Nasdaq: ... acquisition of Cynosure, Inc., a leader in medical aesthetics ... "We are pleased to complete our acquisition ... Michael Davin and the entire Cynosure team to ... medical aesthetics market," said Steve MacMillan , Hologic,s ...
(Date:3/22/2017)... -- TFS is pleased to announce the appointment of ... two global executive positions in Medical Affairs and Clinical Development. Dr. ... and will report to Dr. Montse Barceló , Chief Operating ... ... of medical and scientific expertise gained across leading biopharmaceutical companies and ...
(Date:3/22/2017)... 22, 2017  Levine Cancer Institute today launched ... designed to address lung cancer diagnosis, treatment and ... The mobile lung unit is the first-of-its-kind to ... treatment interventions through integrated mobile technology, traditional treatment ... barriers and a lack of public transportation are ...
Breaking Medicine Technology: